Description
Navitoclax is a medication currently being studied in clinical trials, including for certain types of colorectal cancer. It is being investigated, often in combination with other drugs like trametinib, for patients whose tumors have specific genetic changes, such as KRAS or NRAS mutations, or BCL2 mutations. The trials are primarily in early phases (Phase 1), focusing on determining safe dosages and looking for early signs of effectiveness. It is important to note that navitoclax is not yet an approved treatment for colorectal cancer and is only available within the context of clinical trials.
Mechanism of Action
Navitoclax is designed to target certain proteins within cancer cells that help them survive. Specifically, it inhibits the BCL-2 family of proteins, which are often involved in preventing programmed cell death (apoptosis). By blocking these proteins, navitoclax aims to trigger the death of cancer cells. The specific molecular targets are BCL-2, BCL-xL, and BCL-w. It is being studied in combination with trametinib, which targets proteins involved in cell signaling pathways (like MEK).
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.